<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CANDESARTAN CILEXETIL</span><br/>(can-de-sar'tan ci-lex'e-til)<br/><span class="topboxtradename">Atacand<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin ii receptor antagonist</span><br/><b>Prototype: </b>Losartan<br/><b>Pregnancy Category: </b>C (first trimester); D (second and third trimesters)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>4 mg, 8 mg, 16 mg, 32 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Angiotensin II receptor (type AT<sub>1</sub>) antagonist. Angiotensin II is a potent vasoconstrictor and primary vasoactive hormone of the reninangiotensinaldosterone
         system. Candesartan selectively blocks binding of angiotensin II to the AT<sub>1</sub> receptors found in many tissues (e.g., vascular smooth muscle, adrenal glands).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>This results in blocking the vasoconstricting and the aldosterone-secreting effects of angiotensin II, resulting in an antihypertensive
         effect. Effectively lowers BP from hypertensive to normotensive range.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hypertension, heart failure in conjunction with ACE inhibitor.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known sensitivity to candesartan or any other angiotensin II (AT<sub>1</sub>) receptor antagonist (e.g., losartan, valsartan); primary hyperaldosteronism; bilateral renal artery stenosis; pregnancy
         (category C, first trimester; category D, second and third trimesters); lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Concurrent administration with high-dose diuretics, potassium-sparing diuretics, or potassium salt substitutes; unilateral
         renal artery stenosis; aortic or mitral valve stenosis; hypertrophic cardiomyopathy; CHF; diabetes; lactation; significant
         renal failure.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start at 16 mg q.d. (range 832 mg divided once or twice daily)<br/><br/><span class="indicationtitle">Heart Failure</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start at 4 mcg once daily, double the dose at 2-wk intervals as tolerated by the patient until a dose of 32 mg is reached<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Volume depletion should be corrected prior to initiation of therapy to prevent hypotension.</li>
<li>Dose is individualized and may be given once or twice daily. The daily dose may be titrated up to 32 mg; larger doses are
            not likely to provide additional benefit.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Fatigue, peripheral edema, back pain, arthralgia. <span class="typehead"> CV:</span>  Chest pain. <span class="typehead">GI:</span> Nausea, abdominal pain, diarrhea, vomiting. <span class="typehead">CNS:</span>  Headache, dizziness. <span class="typehead">Respiratory:</span> Cough, sinusitis, upper respiratory infection, pharyngitis, rhinitis. <span class="typehead">Urogenital:</span> Albuminuria. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract; activated by ester hydrolysis during absorption; 15% reaches systemic circulation. <span class="typehead">Peak:</span> Serum concentration, 34 h; therapeutic effect, 24 wk.  <span class="typehead">Duration:</span>  24 h. <span class="typehead">Distribution:</span> &gt;99% protein bound; crosses placenta; distributed into breast milk. <span class="typehead"> Metabolism:</span>  Minimally metabolized in liver. <span class="typehead"> Elimination:</span> Excreted primarily unchanged in bile (67%) and urine (33%). <span class="typehead">Half-Life:</span> 9 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP as therapeutic effectiveness is indicated by decreases in systolic and diastolic BP within 2 wk with maximal effect
            at 46 wk.
         </li>
<li>Monitor for transient hypotension in volume/salt-depleted patients; if hypotension occurs, place in supine position and notify
            physician.
         </li>
<li>Monitor BP periodically; trough readings, just prior to the next scheduled dose, should be made when possible.</li>
<li>Lab tests: Periodically monitor BUN and creatinine, serum potassium, liver enzymes, and CBC with differential.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Inform your physician immediately if you become pregnant.</li>
<li>You may not notice maximum pressure-lowering effect for 6 wk.</li>
<li>Report episodes of dizziness especially when making position changes.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>